Category: Biotechnology

Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-top-line-results-phase-2-clinical-study-nyx-2925 NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects receiving 50 mg dose and in subjects not taking a concomitant analgesic medication NYX-2925 was well-tolerated with no significant adverse

BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2383056 Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS   NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in

Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)

From Startup ARQULE Link to Full Article: 21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing schedule confirmed BURLINGTON, Mass.–(BUSINESS WIRE)–Jan. 9, 2019– ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), today announced results

Genevant Appoints Dr. Margrit Schwarz as Chief Scientific Officer and Head of R&D, and Pete Zorn as Chief Operating Officer

From Startup Genevant Link to Full Article: https://genevant.com/genevant-appoints-dr-margrit-schwarz-as-chief-scientific-officer-and-head-of-rd-and-pete-zorn-as-chief-operating-officer/ Additions bolster Genevant’s leadership position in the RNA therapeutics space with its multiple modality, “pan-RNA” approach BOSTON, MASSACHUSETTS; BURNABY, CANADA; and BASEL, SWITZERLAND – January 7, 2019 – Genevant Sciences, a leading biopharmaceutical company focused on the discovery and development of a

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-highlights-progress-pain-management-and-cinv SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its

AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors

From Startup Avrobio Link to Full Article: Industry leader brings global expertise, including as Shire’s former Global Head of Research and Development, to help further accelerate momentum and growth CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced

Sigilon Therapeutics and MIT Announce Research Collaboration to Advance Programmable Living Therapeutics for Serious Chronic Diseases

From Startup Sigilon Therapeutics Link to Full Article: http://sigilon.com/2019/01/07/sigilon-therapeutics-and-mit-announce-research-collaboration-to-advance-programmable-living-therapeutics-for-serious-chronic-diseases/ CAMBRIDGE, Mass. — January 7, 2019 — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics, and the Massachusetts Institute of Technology today announced a strategic research collaboration. The collaboration leverages cutting-edge synthetic biology approaches developed by professor Ron Weiss

https://decibeltx.com/wp-content/uploads/2019/01/Decibel_Cocoon-Press-Release-Jan-7-2019-1.pdf

From Startup Decibal Therapeutics Decibel Therapeutics has established the world’s first comprehensive drug discovery, development, and translational research platform to discover and develop the first therapeutics to protect, repair, and restore hearing. To serve the over half billion people globally living with hearing loss and related disorders, Decibel is committed